Skip to main content
Clinical Trials/NL-OMON45069
NL-OMON45069
Completed
Not Applicable

The role of regulatory T cells in the pathogenesis of sarcoidosis. - SARTREG

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
sarcoidosis
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
140
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • Sarcoidosis patients should have:
  • \- Newly diagnosed pulmonary sarcoidosis, established using the criteria of the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG)
  • \- Written informed consent
  • \- Age \> 18;Healthy controls should have:
  • \- Written informed consent;
  • \- Age \> 18\.;Tuberculosis patients should have:
  • \- Newly diagnosed tuberculosis with pulmonary caseating granulomas.
  • o Diagnosis is based on European Respiratory Society (ERS) guidelines.
  • \- Written informed consent;
  • \- Age \> 18\.

Exclusion Criteria

  • Sarcoidosis patients may not have:
  • \- Used oral corticosteroids, antimycotica or antibiotics 1 weeks prior to the collection of materials.
  • \- Used immunosuppressive medication or biologicals 3 months prior to the collection of materials.
  • \- A possible infection of the upper\- or lower respiratory tract 4 weeks prior to the collection of materials.
  • \- Other diseases which could influence pulmonary function, granuloma formation and/or the immune system, such as:
  • o Chronic obstructive pulmonary disorder (COPD) or astma in the medical history;
  • o Auto\-immune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), myasthenia gravis or Goodpasture\*s syndrome;
  • o Malignancies;
  • o Human immunodeficiency virus (HIV);
  • o Pregnancy;

Outcomes

Primary Outcomes

Not specified

Similar Trials